



Nomad

Bioscience

inspired by nature and evolution

Antibacterial Biologics



The Threat




of failing bacterial disease control

Antibiotics, the most effective medicine of the XXth century, are failing because of the rampant rise of bacterial resistance, with multi-drug and pan-drug resistant pathogens becoming a common case

We are in the middle of another, silent bacterial, pandemic, and if nothing is done, by 2050, we'll return to 'pre-penicillin era', with 700 thousand Europeans dying yearly from bacterial superbugs

Broad antimicrobial activity of antibiotics and their 'carpet bombing' effect comes with a high price of destroying our gut microbiome, resulting in new diseases, and it causes incompatibility with other modern medicines such as anti-cancer drugs



Imagine

that we could replace non-specifically acting, and rapidly failing, antibiotics with high precision antibacterial biologics with a novel mode of action

- Transformative biologics' therapies for multiple diseases well beyond just a bacterial control
- Focused first-in-human trials in defined patient populations
- Opportunity to build a sustainable, high value biotech company

Bacteriocins



precision antibacterial biologics
invented by nature

Evolved naturally by bacteria to fight same or similar bacterial species

- Highly potent *in vitro* and *in vivo*, rapid acting, multiple modes of action, huge natural diversity, easy to engineer, easy to produce and purify
- Due to novel modes of action, excellent control of multi-/pan-drug resistant bacteria
- Destroy only the pathogenic species while sparing gut microbiome

Bacteriocins


precision antibacterial biologics
invented by nature



Strategy

a match between technology and value creation


- Focus on the most difficult to treat Gram-negative pathogens (*Klebsiella*, *Pseudomonas*, *Escherichia*, etc.), filing patents aiming at a broad exclusivity
- First candidates aim at highly lucrative blood infection (bacteraemia) control market
- Addressing combination therapies, beyond simple antibiotic replacement, with much more attractive pricing
- A pipeline of carefully selected candidates for large strategic markets as well as opportunistic products for niche markets with fast, low-cost market entry



Achievements

With €14 million invested since 2014

- Mined/engineered large libraries of natural and engineered bacteriocins
- Multiple tier selection identified several lead molecules currently in preclinical testing
- Candidates show high efficacy in multiple validated animal models; GLP toxicology for main candidates partially done
- Broad patents filed (in part granted) that will assure Nomad's exclusivity



Recent Progress, Important Value Inflection Points Ahead

- NOMAD has identified six product candidates for preclinical development and plans to complete preclinical studies for two of them soon
- High efficacy of bacteriocin candidates confirmed for various indications including **bacteraemia (primary - focus), intestinal tract infection, lung infection, and eye infection**
- IND enabling (toxicology) studies are ongoing
- CMOs selected for GMP-certified bacteriocin products, necessary for Phase I and II clinical trials
- Ongoing dialogue with clinicians, key opinion leaders and CROs in designing the clinical trials as well as identifying potential participating hospitals and CROs

Next


From start-up to clinical stage company

- Cement foothold as the dominant developer of antibacterial biologics for multiple applications
- Progress quickly with at least two candidates to *first-in-human clinical trials*, complete Phase II for at least two candidates
- Further build-out our team, especially including medical development & clinical expertise
- Expand business development/deal making for synergy/acceleration



Summary


NOMAD is a pioneering discoverer and developer of precision antibacterial biologics for treatment of multidrug resistant Gram-negative bacteria



State of the art platforms with IP on antibacterial precision biologics



Strong team, board and scientific advisors



Risk-hedged pipeline of product candidates



Opportunity for IPO or trade sale as leading clinical stage company